Tetracycline Nextpharm eye ointment 10 mg/g tube 5 g

Topical treatment of superficial ocular infections caused by tetracycline-sensitive microorganisms: Streptococcus spp., Haemophilus influenzae, Escherichia coli, Neisseria gonorrhoeae, Chlamydia trachomatis.

It is used to treat blepharitis, conjunctivitis, keratitis, dacryocystitis, styes, trachoma, and as part of pre- and postoperative prophylaxis in eye surgery.

The drug is also used to prevent neonatal blenorrhea (Neisseria gonorrhoeae).

• active ingredient: tetracycline hydrochloride;
• 1 g of ointment contains tetracycline hydrochloride 10 mg;
• excipients: methyl parahydroxybenzoate (E 218), propyl parahydroxybenzoate (E 216), mineral oil, paraffin, lanolin, white soft paraffin.

Hypersensitivity to the active substance and other components of the drug or to other antibacterial agents of the tetracycline series.

On the part of the organs of vision: blurred vision, burning sensation, sharp pain, itching of the eyes or eyelids, conjunctival hyperemia, eyelid swelling, increased tearing and eye pain.

On the part of the immune system: local allergic reactions – dermatitis, rash, itching, photodermatitis (increased sensitivity to sunlight and UV radiation); generalized allergic reactions – rash, itching/swelling of the face, tongue, throat, dizziness, shortness of breath.

Tetracycline Nextpharm, an ophthalmic ointment for topical use, has no systemic effect; in isolated cases, it may cause irritation of the mucous membrane of the eyelids. Candidiasis may occur, mainly due to overgrowth of Candida albicans; and overgrowth of resistant coliform organisms such as Pseudomonas and Proteus species may also occur.

Myopia in patients taking tetracyclines may be caused by temporary hydration of the lens.

Cases of increased muscle weakness in patients with myasthenia gravis and exacerbation of lupus erythematosus have been reported with prolonged use of tetracycline.

Depending on the severity of the condition, a strip of eye ointment 1–1.5 cm long is applied to the conjunctival fold of the lower eyelid 3–4 times a day, in severe cases up to 6 times a day.

The duration of treatment is determined by the doctor, usually it is from 5 to 7 days. After the symptoms have subsided, the treatment should be continued for another 2–3 days. In more severe eye infections, acute or chronic trachoma, the course of treatment may last up to 1–2 months, and tetracycline can be combined with oral antibiotic use.

To prevent neonatal blenorrhea, a strip of eye ointment 0.5–1 cm long is applied to the conjunctival fold of the newborn’s lower eyelid within 1 hour after birth.

A new tube of ointment is used for each newborn.

When used simultaneously with other ophthalmic drugs, the interval between applications should be at least 10 minutes, and the eye ointment should be applied last.

It is very important to practice hygiene when applying eye ointment, so you should not touch your eyes or surrounding surfaces with the tip of the tube.

Method of application

1. Before the first opening, the protective tape between the cap and the tube must not be broken.
2. A strip of eye ointment (1–1.5 cm) is carefully applied to the conjunctival sac of the affected eye so that the tip of the tube does not touch the eyelids or surrounding surfaces.
3. The eyelids are closed for 1–2 minutes and the ointment is distributed over the entire surface by moving the eyeball in different directions.
4. Use a clean tissue to remove excess ointment from the eyelids and eyelashes. Use another clean tissue to wipe the tip of the tube and close it tightly.
5. If it is necessary to apply tetracycline to the other eye, repeat all the steps described.

Use during pregnancy or breastfeeding

During the 2nd and 3rd trimesters of pregnancy, the drug should be used with extreme caution and only after a careful assessment of the benefit/risk ratio by the doctor, as there may be an undesirable effect on the development of the skeleton and bone growth of the fetus.

Tetracycline is excreted in breast milk after oral administration. There are no data on the passage of tetracycline for ophthalmic use into breast milk, therefore, during breastfeeding, its use is recommended only after a physician has assessed the benefit/risk ratio.

Children

The drug is used in newborns only for the prevention of blenorrhea. The drug should not be prescribed to children under 8 years of age.

Ability to influence reaction speed when driving vehicles or other mechanisms

As with all ophthalmic agents, temporary blurred vision or other visual disturbances may occur, which may affect the ability to drive or use machines. Patients should refrain from driving or using machines until visual acuity is restored.

There are no reports of overdose with topical tetracycline.

There are no data on overdose as a result of accidental or intentional ingestion of the drug.

When topically using tetracycline in ophthalmology, it should be borne in mind that its bacteriostatic action may interfere with the bactericidal action of penicillins, cephalosporins and aminoglycosides. It is recommended to avoid their simultaneous use, both topically and systemically.

The use of tetracycline in patients using contact lens solution containing 0.004% thiomersal has been associated with ocular reactions of varying severity (eye redness, irritation, blepharitis), so their concomitant use should be avoided.

The concomitant use of ophthalmic tetracycline and topical corticosteroids should be avoided.

You should not use cosmetics containing retinoids while using tetracycline.

Some patients taking tetracycline have developed eye inflammation after concomitant use of ophthalmic preparations containing the preservative thiomersal.

Store in original packaging at a temperature not exceeding 25 ° C. Keep out of the reach of children.